Monte Rosa Net Income Over Time
| GLUE Stock | USD 17.92 0.58 3.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Monte Rosa Performance and Monte Rosa Correlation. Will Biotechnology sector continue expanding? Could Monte diversify its offerings? Factors like these will boost the valuation of Monte Rosa. Market participants price Monte higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Monte Rosa data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.32 | Revenue Per Share | Quarterly Revenue Growth 0.385 | Return On Assets | Return On Equity |
Monte Rosa Therapeutics's market price often diverges from its book value, the accounting figure shown on Monte's balance sheet. Smart investors calculate Monte Rosa's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Monte Rosa's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Monte Rosa Therapeutics and related stocks such as Day One Biopharmaceu, Arvinas, and Replimune Group Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (95.5 M) | (85.9 M) | (90.2 M) |
| ARVN | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (24 M) | (41.5 M) | (62.1 M) | (111.8 M) | (183.2 M) | (271.9 M) | (367.3 M) | (198.9 M) | (179 M) | (188 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| TBPH | (109.3 M) | (109.3 M) | (9.6 M) | (156.3 M) | (237 M) | (182.2 M) | (190.7 M) | (285.4 M) | (215.5 M) | (236.5 M) | (278 M) | (199.4 M) | 872.1 M | (55.2 M) | (56.4 M) | (64.9 M) | (68.1 M) |
| AVBP | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
| GERN | (10.7 M) | (96.9 M) | (68.9 M) | (38.4 M) | (35.7 M) | 46 K | (29.5 M) | (27.9 M) | (27 M) | (63.6 M) | (75.6 M) | (116.1 M) | (141.9 M) | (184.1 M) | (174.6 M) | (157.1 M) | (149.3 M) |
| VIR | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (115.9 M) | (174.7 M) | (298.7 M) | 528.6 M | 515.8 M | (615.1 M) | (522 M) | (469.8 M) | (446.3 M) |
| DNA | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (126.6 M) | (1.8 B) | (2.1 B) | (892.9 M) | (547 M) | (492.3 M) | (516.9 M) |
| VALN | (1.2 M) | (4.4 M) | (14.8 M) | (24.1 M) | (26.3 M) | (20.6 M) | (49.2 M) | (11.5 M) | 3.3 M | (1.7 M) | (64.4 M) | (73.4 M) | (143.3 M) | (101.4 M) | (12.2 M) | (11 M) | (11.6 M) |
| MGTX | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (31 M) | (82.9 M) | (54.7 M) | (58 M) | (79.6 M) | (129.6 M) | (84 M) | (147.8 M) | (133 M) | (126.4 M) |
Monte Rosa Therapeutics and related stocks such as Day One Biopharmaceu, Arvinas, and Replimune Group Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Monte Rosa Therapeutics financial statement analysis. It represents the amount of money remaining after all of Monte Rosa Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Monte Rosa Therapeutics | GLUE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 321 Harrison Avenue, |
| Exchange | NASDAQ Exchange |
USD 17.92
Check out Monte Rosa Performance and Monte Rosa Correlation. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Monte Rosa technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.